EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

The Diabetes Remission in India (DiRemI) study: Protocol for a prospective matched-control trial

Pramod Tripathi, Nidhi Kadam iD, Diptika Tiwari, Thejas Kathrikolly, Anagha Vyawahare, Baby Sharma, Malhar Ganla, Banshi Saboo

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0306394 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2024. Verfasst von Pramod Tripathi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Freedom From Diabetes Research Foundation, Pune, Maharashtra, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The global rise in diabetes, particularly in India, poses a significant public health challenge, with factors such as limited awareness, financial strain, and cultural considerations hindering its effective management. Although lifestyle changes have shown promising results, their consistent implementation and maintenance continue to pose challenges. Most studies have focused primarily on dietary modifications, overlooking other essential aspects of lifestyle intervention. The DiRemI study aims to address these gaps by evaluating the efficacy of a comprehensive one-year program that combines diet, exercise, psychological support, and medical management to achieve weight loss, diabetes remission, and improved glycemic control among patients with type 2 diabetes (T2D) in India, while also considering the unique needs of the Indian population.

Methods

The DiRemI study is a prospective, open-label, matched-group trial aimed at assessing the impact of a one-year online integrated intensive lifestyle intervention (ILI) comprising dietary modifications, physical activity, psychological support, and medical management on weight loss and remission in adult T2D patients (aged 30–70 years), with a body mass index (BMI) between 25 and 35 kg/m 2 , and disease duration of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansIndiaProspective StudiesMiddle AgedAdultFemaleMaleAgedWeight LossExerciseLife StyleRemission InductionBody Mass Index

Autor:innen und Institutionen

  • Department of Research, Freedom From Diabetes Research Foundation, Pune, Maharashtra, India.
  • Department of Management & Exercise Science, Freedom from Diabetes Clinic, Pune, Maharashtra, India.
  • Department of Medicine, Dia Care- Diabetes Care and Hormone Clinic, Diabetology, Ahmedabad, Gujarat, India.

ORCID-Profile: Nidhi Kadam

Zitieren

APA

Tripathi, P., Kadam, N., Tiwari, D., Kathrikolly, T., Vyawahare, A., Sharma, B., Ganla, M., & Saboo, B. (2024). The Diabetes Remission in India (DiRemI) study: Protocol for a prospective matched-control trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0306394

Vancouver

Tripathi P, Kadam N, Tiwari D, Kathrikolly T, Vyawahare A, Sharma B, et al. The Diabetes Remission in India (DiRemI) study: Protocol for a prospective matched-control trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0306394

BibTeX
@article{Tripathi2024,
  author = {Tripathi, Pramod and Kadam, Nidhi and Tiwari, Diptika and Kathrikolly, Thejas and Vyawahare, Anagha and Sharma, Baby and Ganla, Malhar and Saboo, Banshi},
  title = {The Diabetes Remission in India (DiRemI) study: Protocol for a prospective matched-control trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0306394}
}
Kostenlos starten →